Get the Stockscreener App
0.8159
4.47%
0.0349
After Hours:
.80
-0.0159
-1.95%
Bio Path Holdings Inc Stock (BPTH) Latest News
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
Thyroid Cancer Drugs Market on Track of Significant Expansion by 2031 | Biovista, Vascular Biogenics, Azaya - EIN News
Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising - AccessWire
Bio-Path (BPTH) Stock Price, News & Analysis - MarketBeat
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode - MSN
Pre-market Movers: HSDT, PBM, MTEM, APTO... - RTTNews
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com - Defense World
Bio-Path Holdings Advances Clinical Pipeline for 2025 - TipRanks
Bio-Path readies for key 2025 clinical milestones By Investing.com - Investing.com Australia
Bio-Path provides 2025 clinical, operational update - TipRanks
Bio-Path readies for key 2025 clinical milestones - Investing.com India
Bio-Path Holdings Provides 2025 Clinical and Operational Update - The Manila Times
Bio-Path's DNAbilize Platform Shows Promise in Cancer Trials, Expands to Diabetes Treatment - StockTitan
Evaxion announces plan to implement ADS ratio change - Seeking Alpha
Is This Penny Stock a Buy After a 180% Rally? - MSN
Is This Penny Stock A Buy After A 180% Rally? - Barchart
Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - Citybuzz
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
NoticeTEKNOSCAN SYSTEMS INC., H. SAMUEL HYAMS, PHILIP KAI-HING KUNG and SOON FOO (MARTIN) TAM, File No. 2022-19 - Barchart
Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes - BioWorld Online
Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Pre - GuruFocus.com
Bio-Path Holdings: Promising Preclinical Results for BP1001-A - TipRanks
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Benzinga
Bio-Path More Than Doubles on Preclinical Results of BP1001-A for Obesity - MarketWatch
Industry Leader Climet Partners with Phizzle; One of the First Joint TCO/ROI Value Proposition in Pharma Manufacturing - Newsfile
Bio-Path Holdings Shares Were On The Rise: What's Going On? - Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga
Innovative therapies and military tech drive early trading gains - RagingBull
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Artificial Intelligence (AI) News Live Feed - StockTitan
Wall Street-Heavily Traded - WDRB
Bio-Path (BPTH) Stock Rides High On Promising Trial Results - Stocks Telegraph
Clinical Trials News Live Feed - StockTitan
Bio-Path reports potential obesity treatment success - Investing.com
Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 - StockTitan
VueReal Showcases Industry-First MicroLED Design Reference Kits at CES 2025, Driving Global Innovation Across Key Industries - Newsfile
Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes - MSN
Bullfrog AI CFO Passes Away - Defense World
Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNEWARK, NJ – December 11, 2024 – Rafael Holdings, Inc. (NYSE: RFL) released its financial results for the first quarter of fiscal year 2025, ended October 31, 2024. The company announ - Defense World
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - Defense World
SouthState (NASDAQ: SSB) Receives Regulatory Approvals for Merger with Independent Bank Group - Defense World
Bio-Path Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Bio-Path Holdings faces Nasdaq delisting over share price - Investing.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - The Kingston Whig-Standard
Bio-Path Holdings Shifts Focus to Metabolic Program - TipRanks
CNB Financial Services, Inc. goes ex dividend tomorrow - MSN
VueReal Highlights Revolutionary MicroLED Solutions at CES 2025 - Newsfile
Bio-Path refocuses on diabetes drug amid trial challenges By Investing.com - Investing.com South Africa
Stonegate Capital Partners Updates Coverage on Aemetis, Inc. (AMTX) Q3 2024 - Newsfile
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):